Home > Dermatology > EADV 2022 > Combined TYK2/JAK1 inhibition shows promise in hidradenitis suppurativa

Combined TYK2/JAK1 inhibition shows promise in hidradenitis suppurativa

Presented By
Prof. Alexandra Kimball, Harvard Medical School, Boston, USA
Conference
EADV 2022
Brepocitinib demonstrated significant efficacy in Hidradenitis Suppurativa Clinical Response (HiSCR) and flare reduction in hidradenitis suppurativa (HS). The other 2 agents that were tested in the same trial, did not meet the primary endpoint. A study design novel to dermatology was used to investigate 3 experimental agents with different modes of action versus placebo in a phase 2b study (NCT04092452) on patients with moderate-to-severe HS, i.e. Hurley stages 2 and 3 [1]. A total of 194 participants were included in the different treatment and placebo groups of this umbrella study. “This design allows you to pool the placebo groups to evaluate against all the different measures at the end,” Prof. Alexandra Kimball (Harvard Medical School, Boston, USA) explained. The active study drugs included the IRAK4 inhibitor PF-06650833 (400...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on